Kuros Biosciences (KURN) AI Stock Analysis

• Market Cap: CHF906.33M
• Dividend Yield: N/A
• Average Volume (3M): 175.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: 125.11%
• EPS Growth: 69.27%
• Country: CH
• Employees: 122
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 38,450,130
• 10 Day Avg. Volume: 112,088
• 30 Day Avg. Volume: 175,151
• PEG Ratio: -4.09
• Price to Book (P/B): 15.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 460.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: CHF27.00 ▲(8.87%Upside)

Kuros Biosciences is on a growth trajectory with strong revenue increases and cash flow improvements, supported by a robust balance sheet. However, profitability remains a challenge, resulting in a low valuation score. Technical indicators are positive, suggesting potential for future gains. The absence of dividend yield and negative P/E ratio are significant drawbacks.

Kuros Biosciences Business Overview & Revenue Model

Company Description

Kuros Biosciences (KURN) is a biotechnology company specializing in the development and commercialization of innovative products for tissue repair and regeneration. Operating within the healthcare sector, Kuros focuses on advanced biomaterials and biologics designed to enhance bone healing and surgical outcomes. Their core products are primarily aimed at addressing orthopedic and spinal conditions, providing surgeons with tools to improve patient recovery processes.

How the Company Makes Money

Kuros Biosciences generates revenue through the sale of its proprietary biomaterial and biologic products designed for use in tissue repair and bone regeneration. The company's key revenue streams include direct sales of its products to healthcare providers, hospitals, and specialized clinics. Additionally, Kuros may engage in strategic partnerships or licensing agreements with other biotechnology or pharmaceutical companies, potentially earning milestone payments, royalties, or collaborative funding. The company’s earnings are influenced by its ability to successfully bring new products to market, expand its customer base, and maintain strong relationships with industry partners.

Kuros Biosciences Financial Statement Overview

Summary

Kuros Biosciences is showing strong revenue growth and improving cash flows. The balance sheet is robust with minimal debt, providing stability. However, the company faces challenges in profitability, as reflected by negative profit margins and return on equity.

Income Statement

The company has demonstrated strong revenue growth with a remarkable increase from CHF 33.56 million in 2023 to CHF 75.55 million in 2024. The gross profit margin is healthy at 82.09%. However, the net profit margin remains negative at -4.92%, indicating the company is still incurring losses. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows strength with a significant equity base, as indicated by the equity ratio of 69.46%. The debt-to-equity ratio is low at 0.03, suggesting minimal leverage. The return on equity remains negative at -6.32%, reflecting the company's current unprofitability.

Cash Flow

Cash flow from operations has improved significantly, turning positive in 2024 to CHF 3.14 million. The free cash flow also shows a positive trend, indicating better cash management. The free cash flow to net income ratio is positive, suggesting efficient cash conversion despite net losses.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
75.56M	33.56M	17.99M	13.81M	4.04M
	Gross Profit
62.03M	23.94M	10.77M	10.07M	1.67M
	EBIT
-5.00M	-13.19M	-13.45M	-8.77M	-11.68M
	EBITDA
-561.00K	-6.84M	-8.84M	-5.29M	-8.58M
	Net Income Common Stockholders
-3.72M	-13.73M	-14.60M	-7.54M	-11.52M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
17.46M	14.21M	24.07M	28.62M	28.39M
	Total Assets
84.54M	71.46M	82.95M	91.34M	94.36M
	Total Debt
1.79M	2.14M	1.91M	2.15M	2.34M
	Net Debt
-15.67M	-12.06M	-22.15M	-26.48M	-26.05M
	Total Liabilities
25.79M	14.75M	14.09M	14.36M	9.76M
	Stockholders Equity
58.75M	56.71M	68.86M	76.98M	84.60M
Cash Flow		Free Cash Flow
2.03M	-9.17M	-7.75M	-5.83M	-9.46M
	Operating Cash Flow
3.14M	-8.84M	-7.35M	-5.45M	-9.24M
	Investing Cash Flow
-1.11M	-326.00K	-400.00K	-374.00K	-220.00K
	Financing Cash Flow
1.34M	-171.00K	3.22M	6.08M	17.08M

Kuros Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:KURN, the sentiment is Positive. The current price of 24.8 is above the 20-day moving average (MA) of 24.64, above the 50-day MA of 22.60, and above the 200-day MA of 21.74, indicating a bullish trend. The MACD of 0.55 indicates Positive momentum. The RSI at 52.69 is Neutral, neither overbought nor oversold. The STOCH value of 29.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:KURN.

Kuros Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	75 Outperform	CHF613.65M	7.87		―	32.30%	631.04%
NWRN	66 Neutral	$153.70M	10.90		―	450.19%	―
KURN	65 Neutral	CHF906.33M	―	-6.44%	―	125.11%	69.27%
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
IDIA	51 Neutral	CHF452.98M	―		―	11.61%	-356.20%
MOLN	47 Neutral	CHF120.72M	―	-40.40%	―	-66.82%	4.14%
SANN	44 Neutral	CHF134.06M	2.58	-93.91%	―	-62.17%	-166.33%

Kuros Biosciences Corporate Events

Kuros Biosciences Achieves 82% Sales Growth in Q1 2025

Kuros Biosciences reported an 82% year-over-year increase in sales for the first quarter of 2025, with total medical device sales reaching USD 28.8 million. The company achieved a significant milestone with monthly revenues surpassing USD 10 million for the first time. Kuros is proactively expanding its global footprint, with MagnetOs products gaining commercial clearance in Brazil and Lebanon, and is taking strategic steps to mitigate potential impacts from upcoming U.S. tariffs by increasing inventory and diversifying production. Recent clinical studies have demonstrated high fusion rates for MagnetOs in high-risk patients, further validating its efficacy and supporting the company’s growth momentum.

Kuros Biosciences Achieves Record Growth and Strategic Expansion in 2024

Kuros Biosciences reported a significant increase in sales for 2024, driven by the success of its MagnetOs product, which saw a 136% rise in direct sales. The company achieved its first positive EBITDA and surpassed the cash flow breakeven point, marking a transformative year. Kuros secured a strategic agreement with Medtronic to enhance MagnetOs’ adoption in the U.S., expanded its market reach, and continued to innovate with new applications and technologies. The company anticipates continued growth, with plans to expand into new markets and expects robust sales growth in the coming years.